8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 5, 2026·SEC
Clene Inc.(CLNN)Earnings, Financials & Key Ratios
CLNN•NASDAQ
$6.06
Price updated Jun 27, 2026
AboutClene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Show more
- Revenue$200K-41.5%
- EBITDA-$22M+31.4%
- Net Income-$26M+33.6%
- EPS (Diluted)-2.65+53.3%
- Gross Margin78.5%-1.3%
- EBITDA Margin-10794%-17.4%
- Operating Margin-11541.5%-19.3%
- Net Margin-13086.5%-13.6%
CLNN Price & Volume
Clene Inc. (CLNN) stock price & volume — 10-year historical chart
Loading chart...
Clene Faces Severe Liquidity And Solvency Risks
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Insolvency and dilutive financing
"Clene Inc. faces a precarious financial outlook characterized by a negligible revenue base of $15,000 in 2026Q1 and a persistent inability to achieve operational profitability. The company's reliance on high-cost R&D spending, which frequently exceeds $5 million per quarter, has led to a rapid erosion of shareholder equity into a negative $18.8 million position. Investors should remain cautious as the firm's dwindling cash reserves of $5.9 million suggest an imminent requirement for dilutive financing or potential insolvency."
Verdict Logic
Negative: The company's negative equity position of -$18.8 million and the rapid depletion of cash reserves to $5.9 million indicate a high probability of significant shareholder dilution or insolvency.
CLNN Growth Metrics
Clene Inc. (CLNN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-0.59%
3 Years-24.94%
TTM-61.71%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-15.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM24.68%
Return on Capital
10 Years-99.52%
5 Years-135.7%
3 Years-160.02%
Last Year-189.2%
CLNN Recent Earnings
Clene Inc. (CLNN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.69-8.4%
$0.64
Rev
$15,000-70.4%
$50,750
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.88-18.9%
$0.74
Rev
$77,000+196.2%
$26,000
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.85-41.7%
$0.60
Rev
$15,000-76.7%
$64,333
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.78-59.2%
$0.49
Rev
$27,000-51.0%
$55,140
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.69vs $0.64-8.4% | $15,000vs $50,750-70.4% |
| Q2 2026 | Mar 12, 2026 | $0.88vs $0.74-18.9% | $77,000vs $26,000+196.2% |
| Q4 2025 | Nov 13, 2025 | $0.85vs $0.60-41.7% | $15,000vs $64,333-76.7% |
| Q3 2025 | Aug 14, 2025 | $0.78vs $0.49-59.2% | $27,000vs $55,140-51.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Clene Inc. (CLNN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.06 | $62.46M | -2.29 | -41.52% | -13086.5% | — | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $2.56 | $260.54M | -2.96 | -86.92% | -1971.7% | -101.76% | — | |
| $3.73 | $64.48M | -2.78 | — | -1070.26% | — | — |
Compare CLNN vs Peers
Clene Inc. (CLNN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLNN SEC Filings & Documents
Clene Inc. (CLNN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CLNN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLNN Frequently Asked Questions
Clene Inc. (CLNN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Clene Inc.'s revenue?
Clene Inc. (CLNN) reported $0.1M in revenue for fiscal year 2025.
How fast is Clene Inc. growing?
Clene Inc. (CLNN) saw revenue decline by 41.5% over the past year.
Is CLNN profitable?
Clene Inc. (CLNN) reported a net loss of $33.5M for fiscal year 2025.
Dividend & Returns
What is Clene Inc.'s free cash flow?
Clene Inc. (CLNN) had negative free cash flow of $18.1M in fiscal year 2025, likely due to heavy capital investments.